In short
This article discusses the ongoing clinical trials of Ecubectedin (PM14), a promising drug being studied in combination with irinotecan for the treatment of various advanced solid tumors. The trials aim to determine the optimal dosage, evaluate safety and effectiveness, and explore potential biomarkers for treatment response. This research could potentially offer new hope for patients with difficult-to-treat cancers who have exhausted standard treatment options.
At a glance
- Drug Name
- Ecubectedin (PM14)
- Trial Phase
- Phase I/II
- Combination
- Ecubectedin with Irinotecan
- Target Population
- Patients with selected advanced solid tumors
- Primary Objectives
- Determine maximum tolerated dose, recommended dose, and evaluate antitumor activity
- Secondary Objectives
- Evaluate safety, pharmacokinetics, pharmacogenetics, and explore biomarkers
- Key Eligibility Criteria
- Advanced solid tumors, ECOG status ≤1, adequate organ function
- Primary Endpoints
- Determination of MTD/RD, Overall Response Rate
- Secondary Endpoints
- Safety assessment, pharmacokinetic analysis, pharmacogenetic evaluation, efficacy measures
What is ECUBECTEDIN?
ECUBECTEDIN, also known as PM14, is a new drug being studied for the treatment of advanced solid tumors. It is a chemical substance that is being developed as a potential cancer treatment. ECUBECTEDIN is currently undergoing clinical trials to evaluate its effectiveness and safety when used in combination with another drug called irinotecan.
Medical Conditions Treated
ECUBECTEDIN is being investigated for the treatment of various advanced solid tumors. These include:
- Gastrointestinal cancers: Such as esophageal carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, biliary tract carcinoma, liver cancer, and certain types of neuroendocrine tumors
- Lung cancers: Including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
- Sarcomas: Such as liposarcoma, leiomyosarcoma, synovial sarcoma, and Ewing's sarcoma
- Gynecological cancers: Including ovarian cancer, endometrial cancer, and cervical cancer
- Breast cancer: Both ductal and lobular carcinomas
- Genitourinary cancers: Such as bladder cancer, kidney cancer, and prostate cancer
- Other cancers: Including mesothelioma, extrapulmonary small cell carcinoma, and adrenocortical carcinoma
These are all considered advanced solid tumors, meaning they are cancers that have spread or are in later stages of development.
How ECUBECTEDIN is Administered
ECUBECTEDIN is administered as an intravenous perfusion, which means it is given directly into the bloodstream through a vein. The drug comes in the form of a powder that is made into a solution for infusion. The maximum dose being studied is 4.5 mg/m² (milligrams per square meter of body surface area).
Clinical Trial Objectives
The ongoing clinical trial for ECUBECTEDIN has several objectives:
- To determine the safe and effective dose of ECUBECTEDIN when used with irinotecan
- To evaluate how well the combination of ECUBECTEDIN and irinotecan works in treating advanced solid tumors
- To assess the safety and side effects of this drug combination
- To study how the drugs interact in the body (pharmacokinetics)
- To investigate genetic factors that might affect how patients respond to the treatment
Eligibility Criteria
To participate in the ECUBECTEDIN clinical trial, patients must meet certain criteria:
- Have an advanced solid tumor that has not responded to standard treatments
- Be in relatively good overall health (ECOG performance status ≤ 1)
- Have adequate bone marrow, kidney, and liver function
- Not have certain heart conditions or active infections
- Not be pregnant or breastfeeding
There are also specific criteria regarding prior treatments and the timing of entering the study.
Safety and Side Effects
As with all cancer treatments, ECUBECTEDIN may cause side effects. The clinical trial is closely monitoring patients for any adverse events. Some potential side effects being watched for include:
- Decreased blood cell counts
- Liver function changes
- Kidney function changes
- Muscle-related issues (monitored through CPK levels)
The study team will grade any side effects according to standardized criteria and may adjust or stop treatment if necessary.
Future Research
The clinical trial for ECUBECTEDIN includes plans for further research:
- Pharmacogenetics: Studying how genetic factors affect how patients respond to the drug
- Pharmacogenomics: Analyzing tumor and blood samples to identify potential biomarkers that might predict who will respond best to the treatment
These studies aim to personalize treatment and improve outcomes for future patients.